Additionally, although CTCs had a different application for tumor prognosis, it is still difficult for CTCs to become common in the clinical practice because at present, the majority of CTCs detection is through epithelial markers (such as EpCAM and cytokeratins) and epithelial cell surface-associated glycoproteins (such as MUC-1) (1), whereas nowadays these methods tend to ignore CTCs with mesenchymal phenotypes. This evidence concerns the gene MUC1 and neoplasm.